文章：

微卫星稳定型结直肠癌的代谢独特性：识别免疫抑制关键因子以提升免疫治疗反应

Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy Response

原文发布日期：2 February 2025

DOI: 10.3390/cancers17030498

类型: Article

开放获取: 是

英文摘要：

Although immune checkpoint inhibitor (ICI) therapy is currently the standard of care in microsatellite-unstable (MSI) metastatic colorectal cancer (CRC), ICI therapy, alone or in combination with other therapies, is not a treatment approach in microsatellite-stable (MSS) CRC, which is present in 95% of patients. In this review, we focus on metabolic singularities—at the transcriptomic (either bulk or single cell), proteomic, and post-translational modification levels—that induce immunosuppression in cancer and specifically in MSS CRC. First, we evaluate the current efficacy of ICIs in limited and metastatic disease in MSS CRC. Second, we discuss the latest findings on the potential biomarkers for evaluating ICI efficacy in MSS CRC using strict REMARK criteria. Third, we review the current evidence on metabolic patterns in CRC tumors and immune cell metabolism to advance our understanding of metabolic crosstalk and to pave the way for the development of combination strategies to enhance ICI efficacy.

摘要翻译： 

尽管免疫检查点抑制剂（ICI）疗法目前是微卫星不稳定（MSI）转移性结直肠癌（CRC）的标准治疗方案，但对于占患者总数95%的微卫星稳定（MSS）型CRC，单独或联合其他疗法的ICI治疗尚未成为有效治疗手段。本综述聚焦于在转录组（包括整体与单细胞层面）、蛋白质组及翻译后修饰水平上诱导癌症——特别是MSS型CRC——免疫抑制的代谢特异性。首先，我们评估了ICI在MSS型CRC局限期及转移性疾病中的现有疗效。其次，依据严格的REMARK标准，探讨了评估MSS型CRC中ICI疗效的潜在生物标志物最新研究进展。最后，系统回顾了当前关于CRC肿瘤代谢模式与免疫细胞代谢的研究证据，以深化对代谢交互作用的理解，并为开发提升ICI疗效的联合治疗策略奠定基础。

原文链接：

Metabolic Singularities in Microsatellite-Stable Colorectal Cancer: Identifying Key Players in Immunosuppression to Improve the Immunotherapy Response